A burst rating indicates the battery discharge rate for short bursts (a few seconds maximum) of extended power
The agency has mandated that Novo Nordisk update product labeling to include this "very rare" side effect warning a significant development for patients and healthcare providers who have been largely unaware of this serious risk
Meal-dependent patterns become clear
Pain and Physical Function Improvements TRIUMPH-4's co-primary endpoint focused on knee osteoarthritis pain, measured by the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain subscale: WOMAC Pain Score Reductions: Retatrutide 9mg: -4.5 points (75.8% reduction) Retatrutide 12mg: -4.4 points (73.3% reduction) Placebo: -2.4 points (40.3% reduction) Participants also experienced substantial improvements in physical function, with WOMAC physical function subscale scores improving by: Retatrutide 9mg: -4.1 points Retatrutide 12mg: -4.2 points Placebo: -2.1 points Perhaps most remarkably, a post-hoc analysis revealed that 14.1% of participants on 9mg and 12.0% on 12mg became completely pain-free at 68 weeks, compared to just 4.2% on placebo
Common GLP-1 medications available in the UK include: GLP-1 receptor agonists: Semaglutide (Ozempic for diabetes, Wegovy for weight management) Liraglutide (Victoza for diabetes, Saxenda for weight management) Dulaglutide (Trulicity for diabetes) Dual GIP/GLP-1 receptor agonist: Tirzepatide (Mounjaro for diabetes, Zepbound for weight management) These medications are administered via subcutaneous injection, typically weekly or daily depending on the specific formulation
